<DOC>
	<DOCNO>NCT02093195</DOCNO>
	<brief_summary>Present treatment chronic obstructive pulmonary disease ( COPD ) certain role reduce COPD exacerbation hospitalization , improve life quality , postpone lung function decline . But patient severe COPD , current treatment partially alleviate symptom little role lung function decline . In randomized , multicenter study , investigator evaluate safety efficacy bosentan treatment grade Ⅲ Ⅳ COPD patient pulmonary hypertension detect echocardiography . The primary endpoint frequency COPD exacerbation , secondary endpoint include change lung function , 6-min-walk distance ( 6-MWD ) , SGRQ score mMRC/CAT score .</brief_summary>
	<brief_title>Study Bosentan Treatment Stable Severe Chronic Obstructive Pulmonary Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>Aged 18 75 Gold Ⅲ Ⅳ stable COPD Pulmonary hypertension detect echocardiography Acute exacerbation chronic obstructive pulmonary disease Untreated obstructive sleep apnea Restrictive ( total lung capacity &lt; 60 % predict ) lung disease Portal hypertension Chronic liver disease Transaminase increase normal line 3 time ; total bilirubin increase 2 time upper limit normal value Leftsided unrepaired congenital heart disease Patients serious heart diseases Patients 1 , 2 , 4 5 category pulmonary hypertension Unable complete 6 minute walk test Patients receive endothelin receptor antagonists No cooperation complete</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Treatment , COPD , bosentan</keyword>
</DOC>